ACSL4 serves as a novel prognostic biomarker correlated with immune infiltration in Cholangiocarcinoma

• Published in: BMC cancer 2023-05, Vol.23 (1), p.444-444, Article 444
• Main Authors: Liu, Shuochen, Fan, Shilong, Wang, Yirui, Chen, Ruixiang, Wang, Ziyi, Zhang, Yaodong, Jiang, Wangjie, Chen, Yananlan, Xu, Xiao, Yu, Yue, Li, Changxian, Li, Xiangcheng
• Format: Article
• Language: English
• Subjects: ACSL4; Analysis; Bile Duct Neoplasms - genetics; Bile Ducts, Intrahepatic; Biological markers; Biomarkers; Cancer; Carcinoma, Hepatocellular; Cell growth; Cholangiocarcinoma; Cholangiocarcinoma - genetics; Datasets; Diagnosis; Enzymes; Ferroptosis; Gene expression; Genes; Genetic aspects; Genomes; Genomics; GEO; Health aspects; Hepatocellular carcinoma; Humans; Immune infiltration; Infiltration; Ligases; Liver cancer; Liver Neoplasms; Medical prognosis; Metastases; Microenvironments; Oncology, Experimental; Prognosis; TCGA; Tumor Microenvironment - genetics; Tumor-infiltrating lymphocytes; Tumors; Wound healing
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-023-10903-5

Cholangiocarcinoma (CHOL) is the second most common primary hepatic malignant tumor, following hepatocellular carcinoma (HCC). CHOL is highly aggressive and heterogeneous resulting in poor prognosis. The diagnosis and prognosis of CHOL has not improved in the past decade. Acyl-CoA synthetase long-chain family member 4 (ACSL4) is reported to be associated with tumors, however, its role in CHOL has not been revealed. This study is mainly for exploring the prognostic values and potential function of ACSL4 in CHOL. We investigated the expression level and prognostic value of ACSL4 in CHOL based on The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets. TIMER2.0, TISIDB and CIBERSORT databases were utilized to assess the associations between ACSL4 and immune infiltration cells in CHOL. Single-cell sequencing data from GSE138709 was analyzed to study the expression of ACSL4 in different types of cells. ACSL4 co-expressed genes were analyzed by Linkedomics. Additionally, Western Blot, qPCR, EdU assay, CCK8 assay, transwell assay and wound healing assay were performed to further confirm the roles of ACSL4 in the pathogenesis of CHOL. We found that the level of ACSL4 was higher in CHOL and it was correlated with the diagnosis and prognosis of CHOL patients. Then, we observed that the infiltration level of immune cells was related to the level of ACSL4 in CHOL. Moreover, ACSL4 and its co-expressed genes were mainly enriched in metabolism-related pathway and ACSL4 is also a key pro-ferroptosis gene in CHOL. Finally, knockdown of ACSL4 could reverse the tumor-promoting effect of ACSL4 in CHOL. The current findings demonstrated ACSL4 may as a novel biomarker for CHOL patients, which might regulate immune microenvironment and metabolism resulting in poor prognosis.